TARS · Tarsus Pharmaceuticals, Inc.
$69.20
+0.32 (+0.46%)
At close · Aug 14
Market Cap
$3.04B
Shares
43.88M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-06 | 2026-07-31 | |
| 8-K | 2026-08-06 | — | |
| 8-K | 2026-08-06 | 2026-08-05 | |
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-07-13 | — | |
| 8-K | 2026-07-08 | 2026-07-06 | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-29 | 2026-06-25 | |
| Investor Event Transcript | 2026-06-03 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-02 | 2026-06-30 | |
| 8-K | 2026-05-06 | — | |
| 10-Q | 2026-05-06 | 2026-03-31 | |
| DEF 14A | 2026-04-28 | 2026-06-25 | |
| Investor Event Transcript | 2026-03-31 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-02-23 | — | |
| 10-K | 2026-02-23 | 2025-12-31 | |
| 8-K | 2026-02-18 | — | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2025-11-04 | — | |
| 10-Q | 2025-11-04 | 2025-09-30 | |
| 8-K | 2025-08-06 | — | |
| 10-Q | 2025-08-06 | 2025-06-30 | |
| 8-K | 2025-06-18 | 2025-06-12 | |
| 10-Q | 2025-05-01 | 2025-03-31 | |
| 8-K | 2025-05-01 | — | |
| DEF 14A | 2025-04-28 | 2025-06-12 | |
| 8-K | 2025-03-18 | 2025-03-14 | |
| 8-K | 2025-03-13 | 2025-03-12 | |
| 8-K | 2025-02-25 | — | |
| 10-K | 2025-02-25 | 2024-12-31 | |
| 8-K | 2025-01-17 | 2025-01-15 | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-12-19 | 2024-12-16 | |
| 10-Q | 2024-11-13 | 2024-09-30 | |
| 8-K | 2024-11-13 | — | |
| 8-K | 2024-11-05 | 2024-11-01 | |
| 8-K | 2024-08-08 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-06-18 | 2024-06-13 | |
| 8-K | 2024-05-08 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| DEF 14A | 2024-04-26 | 2024-06-13 | |
| 8-K | 2024-04-23 | 2024-04-19 | |
| 8-K | 2024-03-05 | — | |
| 8-K | 2024-03-01 | 2024-02-29 | |
| 8-K | 2024-02-27 | — | |
| 10-K | 2024-02-27 | 2023-12-31 | |
| 8-K | 2024-01-18 | 2024-01-11 | |
| 8-K | 2024-01-08 | — |
Showing 1–50 of 104 filings
Key facts
CIK
1819790
CUSIP
87650L103
13F (30d)
246 filings
243 filers
Visit website
Investor relations